Evidence map›Paper›PMID 31056293›Full record

Observational studyLancet (London, England)2019

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.

Alison J Rodger, Valentina Cambiano, Tina Bruun, Pietro Vernazza, Simon Collins, Olaf Degen, Giulio Maria Corbelli, Vicente Estrada, Anna Maria Geretti, Apostolos Beloukas and 27 more

3 registry-linked trialsOpen access · bronzeAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Lancet (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 498 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
498citing papers in PubMed, 12 pooled it
77.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04712058 naunknown statusnot on this mapstarted 2021, after this paper: background citation

A Multicenter Clinical Trial to Evaluate the Feasibility and Outcome of Same-day Antiretroviral Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) Among Patients Testing Positive by HIV Confirmatory Tests

TypeinterventionalSponsorNational Taiwan University HospitalRan2021 to 2023Enrolled200ConditionsHIV InfectionsArmsBictegravir / Emtricitabine / Tenofovir Alafenamide Oral Tablet [Biktarvy]
NCT05278559 unknown statusnot on this mapstarted 2022, after this paper: background citation

Can Undetectable (Viral Load) = Untransmissible (Virus) Change the Life Course of Adolescents Living the HIV in Africa

TypeobservationalSponsorCentre for Sexual Health and HIV/AIDS Research ZimbabweRan2022 to 2024Enrolled300ConditionsHIV/AIDS
NCT05333679 nacompletednot on this mapstarted 2022, after this paper: background citation

Urine Tenofovir Point-of-care Test to Identify Patients in Need of ART Adherence Support (UTRA Study)

TypeinterventionalSponsorUniversity of California, San FranciscoRan2022 to 2025Enrolled200ConditionsRisk ReductionArmsUTRA, UTRA feedback
3 · Its place in the literature

Who cites it

498 citing papers in PubMed, 12 syntheses or guidelines pooled it, 975 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Canadian guideline on HIV pre- and postexposure prophylaxis: 2025 update.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Guideline
  6. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Guideline
  7. Pooled it
  8. Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - CDC Recommendations, United States, 2025.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2025
    Guideline
  9. Pooled it
  10. German evidence- and consensus-based guideline on the management of penile urethritis.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025
    Guideline
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

438 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

37 authors at 20 institutions in 14 countries.

Alison J RodgerInstitute for Global Health, University College London, London, UK. Electronic address: alison.rodger@ucl.ac.uk.
Valentina CambianoInstitute for Global Health, University College London, London, UK.
Tina BruunDepartment of Infectious Diseases (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Pietro VernazzaDivision of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital, St Gallen, Switzerland.
Simon CollinsHIV i-Base, London, UK.
Olaf DegenUniversity Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Giulio Maria CorbelliEuropean AIDS Treatment Group, Brussels, Belgium.
Vicente EstradaHospital Clinico San Carlos and Universidad Complutense, Madrid, Spain.
Anna Maria GerettiInstitute of Infection and Global Health, University of Liverpool, Liverpool, UK.
Apostolos BeloukasInstitute of Infection and Global Health, University of Liverpool, Liverpool, UK; Department of Biomedical Sciences, University of West Attica, Athens, Greece.
Dorthe RabenDepartment of Infectious Diseases (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Pep CollAIDS Research Institute-IrsiCaixa, Hospital Universitari Germans Trias i Pujol and BCN Checkpoint, Badalona and Barcelona, Spain.
Andrea AntinoriIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani IRCCS, Rome, Italy.
Nneka NwokoloChelsea and Westminster NHS Foundation Trust, London, UK.
Armin RiegerMedical University of Vienna, Vienna, Austria.
Jan M PrinsAmsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Anders BlaxhultVenhälsan, Södersjukhuset, Stockholm, Sweden.
Rainer WeberDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Arne Van EedenDC Klinieken, Amsterdam, Netherlands.
Norbert H BrockmeyerCentre for Sexual Health and Medicine, Walk in Ruhr, Ruhr University Bochum, Bochum, Germany.
Amanda ClarkeBrighton and Sussex University Hospitals NHS Trust, and Brighton and Sussex Medical School, Brighton, UK.
Jorge Del Romero GuerreroCentro Sanitario Sandoval, Madrid, Spain.
Francois RaffiInfectious Diseases Department, University Hospital (Centre Hospitalier Universitaire de Nantes) Hotel-Dieu, and INSERM UIC 1413 Nantes University, Nantes, France.
Johannes R BognerMedizinische Klinik und Poliklinik IV, University Hospital Munich, Munich, Germany.
Gilles WandelerDepartment of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Jan GerstoftRigshospitalet, Copenhagen, Denmark.
Felix GutiérrezHospital General de Elche and Universidad Miguel Hernández, Alicante, Spain.
Kees BrinkmanOnze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, Netherlands.
Maria KitchenMedical University Innsbruck, Innsbruck, Austria.
Lars OstergaardAarhus University Hospital, Skejby, Denmark.
Agathe LeonHospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain.
Matti RistolaHelsinki University Hospital and University of Helsinki, Helsinki, Finland.
Heiko JessenPraxis Jessen(2) + Kollegen, Berlin, Germany.
Hans-Jürgen StellbrinkICH Study Centre, Hamburg, Germany.
Andrew N PhillipsInstitute for Global Health, University College London, London, UK.
Jens LundgrenDepartment of Infectious Diseases (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
PARTNER Study Group
Innsbruck Medical University · ATLMU Klinikum · DEUniversity College London · GBInfektionsmedizinisches Centrum Hamburg · DEInserm · FRIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITOrthopädische Praxis · DEUniversity of Bern · CHUniversity of Copenhagen · DKAarhus University Hospital · DKAmsterdam University Medical Centers · NLBrighton and Sussex Medical School · GBChelsea and Westminster Hospital NHS Foundation Trust · GBDutch Cancer Society · NLHospital Clínic de Barcelona · ESHospital Clínico San Carlos · ESIrsiCaixa · ESKantonsspital St. Gallen · CHMedical University of Vienna · ATOLVG · NL

Funding

Department of Health
6 · The paper itself

Abstract

backgroundThe level of evidence for HIV transmission risk through condomless sex in serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral therapy (ART) is limited compared with the evidence available for transmission risk in heterosexual couples. The aim of the second phase of the PARTNER study (PARTNER2) was to provide precise estimates of transmission risk in gay serodifferent partnerships.

methodsThe PARTNER study was a prospective observational study done at 75 sites in 14 European countries. The first phase of the study (PARTNER1; Sept 15, 2010, to May 31, 2014) recruited and followed up both heterosexual and gay serodifferent couples (HIV-positive partner taking suppressive ART) who reported condomless sex, whereas the PARTNER2 extension (to April 30, 2018) recruited and followed up gay couples only. At study visits, data collection included sexual behaviour questionnaires, HIV testing (HIV-negative partner), and HIV-1 viral load testing (HIV-positive partner). If a seroconversion occurred in the HIV-negative partner, anonymised phylogenetic analysis was done to compare HIV-1 pol and env sequences in both partners to identify linked transmissions. Couple-years of follow-up were eligible for inclusion if condomless sex was reported, use of pre-exposure prophylaxis or post-exposure prophylaxis was not reported by the HIV-negative partner, and the HIV-positive partner was virally suppressed (plasma HIV-1 RNA <200 copies per mL) at the most recent visit (within the past year). Incidence rate of HIV transmission was calculated as the number of phylogenetically linked HIV infections that occurred during eligible couple-years of follow-up divided by eligible couple-years of follow-up. Two-sided 95% CIs for the incidence rate of transmission were calculated using exact Poisson methods.

findingsBetween Sept 15, 2010, and July 31, 2017, 972 gay couples were enrolled, of which 782 provided 1593 eligible couple-years of follow-up with a median follow-up of 2·0 years (IQR 1·1-3·5). At baseline, median age for HIV-positive partners was 40 years (IQR 33-46) and couples reported condomless sex for a median of 1·0 years (IQR 0·4-2·9). During eligible couple-years of follow-up, couples reported condomless anal sex a total of 76 088 times. 288 (37%) of 777 HIV-negative men reported condomless sex with other partners. 15 new HIV infections occurred during eligible couple-years of follow-up, but none were phylogenetically linked within-couple transmissions, resulting in an HIV transmission rate of zero (upper 95% CI 0·23 per 100 couple-years of follow-up).

interpretationOur results provide a similar level of evidence on viral suppression and HIV transmission risk for gay men to that previously generated for heterosexual couples and suggest that the risk of HIV transmission in gay couples through condomless sex when HIV viral load is suppressed is effectively zero. Our findings support the message of the U=U (undetectable equals untransmittable) campaign, and the benefits of early testing and treatment for HIV.

fundingNational Institute for Health Research.

Indexed as

Homosexuality, MaleUnsafe SexAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCondomsHIV SeropositivityHumansMaleMiddle AgedProspective StudiesSexual PartnersViral LoadAnti-HIV Agents

Identifiers

PMID31056293
PMCPMC6584382
OpenAlexW2943039121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.